Home > Resources > Company Profiles > Boston Scientific Corporation

Boston Scientific Corporation (BSX)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

James R. Tobin , CEO/President/Director

www.bostonscientific.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A developer, manufacturer and marketer of medical devices that are used in carrdiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, oncology, endoscopy, urology, gynecology and neuromodulation.

News Feeds

Boston Scientific shares fall to 52-week low AP
Oct 10 2008
FDA approves long-delayed Boston Scientific stent AP
Oct 10 2008
Midday Glance: Medical companies AP
Oct 10 2008
Early Glance: Medical companies AP
Oct 10 2008
Final Glance: Medical Devices companies AP
Oct 09 2008
Boston Scientific: sell-off was involuntary AP
Oct 09 2008
Boston Scientific outlines 3Q charges, gains AP
Oct 08 2008
Final Glance: Medical companies AP
Oct 07 2008
Boston Scientific $703M infringement appeal denied Boston
Oct 06 2008
Sector Snap: Medical device companies AP
Oct 03 2008

Portfolio Blogs

How to Break a CPDO
Sep 12 2007

Press Releases

Angiotech's corporate partner, Boston Scientific, announces FDA approval of second-generation TAXUS(R) Liberte(R) drug-eluting stent Oct-10-2008, 02:31PM EDT
Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent Oct-10-2008, 11:12AM EDT
Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008 Oct-10-2008, 08:30AM EDT
Boston Scientific Comments on Involuntary Selling of Its Stock by Co-Founders Oct-09-2008, 09:15AM EDT
Angiotech's corporate partner, Boston Scientific, announces completion of clinical trial enrollment for third-generation drug-eluting stent Oct-08-2008, 04:28PM EDT

News From Around the Web

News

New research on drug-coated stents to be revealed (USA Today)

Oct 11 2008
Boston Sci approved to sell its new heart stent (Minneapolis Star Tribune)

Oct 11 2008
Boston Scientific shares fall to 52 - week low amid broader losses and involuntary selling (Canadian Business Online)

Oct 10 2008
Boston Scientific revises estimates (BizJournals)

Oct 10 2008
Heart Conference To Focus On Expanded Stent Use, Heart Valves (Morningstar)

Oct 10 2008
Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS Liberte Drug-Eluting Stent (PharmaLive)

Oct 10 2008
Early Glance: Medical companies (Boston Globe)

Oct 10 2008
Boston Scientific bruised by credit mess, research could be next (Boston Herald)

Oct 10 2008
Boston Scientific Announces Third Quarter Adjustments (Examiner.com: Anchorage, Alaska)

Oct 08 2008

Blogs

Boston Scientific share price fall to 52-week low linked to liquidation of Lehman Brothers (FinFacts Ireland)

Oct 10 2008

Employees

Number of Employees: 24,500

Revenue per Employee: $289,161

Top Executives

Sam R. Leno, Executive VP, Divisional/CFO

Lucia L. Quinn, Divisional Executive VP

William F. McConnell, Jr., Senior VP, Divisional

Fredericus A. Colen, President, Divisional

David McFaul, Senior VP, Divisional

James (Jim) Gilbert, Executive VP, Divisional

Jeffrey D. Capello, CPA, Senior VP/Chief Accounting Officer/Controller

Paul Donovan, Divisional Senior VP

Stephen F. Moreci, Divisional President/Senior VP

Kenneth J. Pucel, Executive VP, Divisional

Mark C. Bartell, Senior VP, Divisional

Jeffrey H. Goodman, Executive VP, Geographical

Brian R. Burns, Divisional Senior VP

Dr. Donald S. Baim, M.D., Chief Medical Officer/Chief Scientific Officer/Executive VP

William H. (Hank) Kucheman, President, Divisional/Senior VP

Board of Directors

Nancy-Ann DeParle, Director

J. Raymond Elliott, Director

Joel L. Fleishman, Director

N. J. Nicholas, Jr., Director

John E. Pepper, Jr., Director

Pete M. Nicholas, Founder/Chairman of the Board/Director

Senator Warren B. Rudman, Director

Ursula M. Burns, Director

Dr.Marye Anne Fox, Director

Dr.Kristina M. Johnson, Director

John E. Abele, Founder/Director

Ray J. Groves, Director

Dr.Uwe E. Reinhardt, Ph.D., Director

Dr.Ernest Mario, Ph.D., Director

Financials

Quarterly

Annual

Income Statement	07/2008	04/2008	02/2008	10/2007
Sales	739 Mil.	769 Mil.	NA	730 Mil.
Gross Operating Profit	1.28 Bil.	1.28 Bil.	2.15 Bil.	1.32 Bil.
Operating Income before D & A (EBITDA)	313 Mil.	372 Mil.	2.15 Bil.	328 Mil.
Total Income Before Interest Expenses (EBIT)	218 Mil.	593 Mil.	2.15 Bil.	-112 Mil.
Total Net Income	98 Mil.	322 Mil.	-458 Mil.	-272 Mil.
Basic EPS, Total	0.07	0.21	-0.31	-0.18
Diluted EPS, Total	0.07	0.21	-0.31	-0.18

BALANCE STATEMENT	07/2008	04/2008	02/2008	10/2007
Cash and Equivalents	1.62 Bil.	1.74 Bil.	1.45 Bil.	1.24 Bil.
Total Assets	5.17 Bil.	5.24 Bil.	6.2 Bil.	4.69 Bil.
Total Liabilities	3.04 Bil.	3.39 Bil.	3.28 Bil.	3.38 Bil.
Total Capitalization	22.65 Bil.	22.7 Bil.	23.03 Bil.	23.42 Bil.

Cash Flow	07/2008	04/2008	02/2008	10/2007
Net Cash From Continuing Operations	NA	NA	NA	626 Mil.
Net Cash From Investing Activities	NA	NA	NA	-436 Mil.
Net Cash From Financing Activities	NA	NA	NA	-624 Mil.
Net Change in Cash & Cash Equivalents	NA	NA	NA	-431 Mil.

Income Statement	2008	2007	2006	2005
Sales	3.18 Bil.	1.96 Bil.	1.22 Bil.	1.13 Bil.
Gross Operating Profit	5.17 Bil.	5.86 Bil.	5.06 Bil.	4.5 Bil.
Operating Income before D & A (EBITDA)	1.09 Bil.	2.18 Bil.	2.56 Bil.	2.18 Bil.
Total Income Before Interest Expenses (EBIT)	2.2 Bil.	-3.1 Bil.	981 Mil.	1.56 Bil.
Total Net Income	-495 Mil.	-3.58 Bil.	628 Mil.	1.06 Bil.
Basic EPS, Total	-0.33	-2.81	0.75	1.27
Diluted EPS, Total	-0.33	-2.81	0.75	1.24

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	1.45 Bil.	1.67 Bil.	848 Mil.	1.3 Bil.
Total Assets	6.2 Bil.	4.9 Bil.	2.63 Bil.	3.29 Bil.
Total Liabilities	3.28 Bil.	2.63 Bil.	1.48 Bil.	2.6 Bil.
Total Capitalization	23.03 Bil.	24.19 Bil.	6.15 Bil.	5.16 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	1.84 Bil.	903 Mil.	1.8 Bil.
Net Cash From Investing Activities	NA	-9.31 Bil.	-551 Mil.	-1.62 Bil.
Net Cash From Financing Activities	NA	8.44 Bil.	-954 Mil.	439 Mil.
Net Change in Cash & Cash Equivalents	NA	979 Mil.	-607 Mil.	625 Mil.

Boston Scientific Corporation (BSX)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request